NEW DELHI (Reuters) – India stated on Friday month-to-month manufacturing capability of its homegrown COVID-19 shot will likely be raised to just about 100 million doses by September, because it tries to beat a scarcity amid a document surge in circumstances.
“The present manufacturing capability of indigenously developed Covaxin vaccine will likely be doubled by Could-June 2021 after which elevated almost 6-7 fold by July-August 2021,” the Ministry of Science & Know-how stated in a press release, pegging present capability at 10 million doses.
(Reporting by Nallur Sethuraman; Modifying by Jon Boyle)
Copyright 2021 Thomson Reuters.
